Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 and Docetaxel in SCCHN
NCT01285635Phase 2
Key facts
- Status
- Terminated
- Start
- Jun 2010
- Primary completion
- Dec 2012
- Countries
- 1
- Sponsor
- University of Michigan Rogel Cancer Center
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Conditions
- squamous cell carcinoma of the head and neck (HNSCC)
01
Overview
Phase 2, randomised, open-label trial of r-(-)-gossypol acetic acid in squamous cell carcinoma of the head and neck (HNSCC), sponsored by University of Michigan Rogel Cancer Center. Started Jun 2010; status: terminated.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Adults with histologically confirmed SCCHN (Stage IVC or advanced/recurrent) who have received no more than two prior systemic regimens and have measurable disease.
04
Registry description
This study will examine the effects of an investigational drug called AT-101 in combination with an FDA approved cancer drug called Docetaxel. It is hoped that AT-101 will help the Docetaxel to have a better effect in slowing or stopping cancer cell growth. This study will help the researchers learn what effects, if any, the combination of AT-101 and Docetaxel has on your cancer. For instance, will the combination cause your tumor(s) to shrink or stop growing? The researchers will also learn about the safety of the combination of AT-101 and Docetaxel. For instance, are there any side…
Beyond the preview
Go deeper on NCT01285635.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01285635.